This contemporary, international, evidence-informed guidance aims to achieve the greatest
good for the greatest number of people with familial hypercholesterolaemia (FH) across …

Background: Atherosclerotic cardiovascular diseases (ASCVD) including myocardial
infarction, stroke and peripheral arterial disease continue to be major causes of premature …

Background: VERVE-101 is an investigational in vivo CRISPR base-editing medicine
designed to alter a single DNA base in the PCSK9 gene, permanently turn off hepatic …

Moreover, over the last few years the approach to treatment of patients with a high
cardiovascular risk has totally changed from treatment aimed at a specific risk factor (ie …

Cardiovascular disease is the leading cause of death in women and men globally, with most
due to atherosclerotic cardiovascular disease (ASCVD). Despite progress during the last 30 …

Lowering the levels of LDL cholesterol in the plasma has been shown to reduce the risk of
atherosclerotic cardiovascular disease (ASCVD). Several other lipoproteins, such as …

Screening in children for familial hypercholesterolaemia: start now Page 1 Screening in children
for familial hypercholesterolaemia: start now Urh Groselj 1 , Albert Wiegman 2 , and Samuel S …

Familial hypercholesterolaemia (FH) is under-recognized and under-treated in Europe
leading to significantly higher risk for premature heart disease in those affected. As treatment …

Bempedoic acid is a new cholesterol-lowering drug, which has recently received US FDA
and EMA approval. This drug targets lipid and glucose metabolism as well as inflammation …

Abstract Purpose of Review Plasma levels of LDL cholesterol (LDL-C) are causally
associated with cardiovascular risk. Reducing LDL-C results in a decreased incidence of …